Hadassah

Drug Company Collaborates with Hadassah Liver Specialist in Fighting Liver Disease

Wednesday, Jan 10 2018

Illustration of the positive impact of Namodenoson, as compared to treatment of animals with a placebo (“vehicle”)

Dr. Rifaat Safadi, head of the Hadassah Medical Organization’s Liver Unit, in its Institute of Gastroenterology and Liver Diseases, is collaborating with Can-Fite BioPharma Ltd. to explore further the healing effects of a new drug that has proven in preclinical studies to mitigate inflammatory diseases of the liver, such as NASH (non-alcoholic steatohepatitis).

The new drug called Namodenoson, Dr. Safadi says, “is unique among today’s NASH drugs under development due to its excellent safety profile and the positive effect on steatosis (accumulation of fat in the liver), inflammation, and fibrosis (liver scarring, which results from dying of liver cells, also referred to as ballooning).”  Improvement in these parameters translates into a significant anti-NASH effect.

Namodenoson has been granted Orphan Drug Designation in the United States and Europe and Fast Track Designation as a second-line treatment for hepatocellular cancer by the United States Food and Drug Administration. It has the potential to be effective in treating other cancers, including colon and prostate cancer, as well as melanoma.

Can-Fite has initiated enrollment for a Phase II study with Namodenoson in NASH and NAFLD (non-alcoholic fatty liver disease) patients who show evidence of active inflammation. The focus will be on measuring the drug’s anti-inflammatory effect and its success in reducing fat in the liver.

A prolific researcher, renowned for his work with NASH, Dr. Safadi is also a member of Can-Fite’s Clinical Advisory Board. “We are privileged to work with Dr. Safadi to further study and advance the drug’s mechanism of action,” notes Pnina Fishman, PhD, Founder and Chief Executive Officer of Can-Fite.

Learn more about the Hadassah Medical Organization.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Feb 21 2019

Hadassah Heart Specialist Performs Revolutionary Repair of Fatal Aortic Condition

Most people with aneurysms have to choose between very risky surgery or waiting for their aneurysm to rupture. Now there’s a new method to repair the deadly medical condition.

READ MORE ›
alt_text

Wednesday, Feb 20 2019

Jerusalem Basketball Star Undergoes Knee Surgery at Hadassah

Chris Johnson, a star basketball player with Hapoel Bank Yahav Jerusalem, underwent successful knee surgery at Hadassah Hospital Mount Scopus.

READ MORE ›
alt_text

Tuesday, Feb 19 2019

Marathoner Is Helicoptered to Hadassah After Collapsing During Race

Shahar David, age 46, had planned to run 10 kilometers in the Dead Sea Marathon, but he collapsed after kilometer 6. A helicopter transported him to Hadassah Hospital Ein Kerem, where he underwent an emergency cardiac catheterization that saved his life.

READ MORE ›
alt_text

Thursday, Feb 7 2019

Six Miscarriages, a Severe Liver Disease, and a Dream

Oshrat Ohana Nagar was a busy newspaper journalist, a self-proclaimed workaholic, and a mother of two children. Shortly after the birth of her second child, however, she began to experience pain throughout her body.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More